Home
/
Voyager Therapeutics, Inc.
/
Financials
/
Quarterly
Voyager Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Voyager Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2018
Sep 30, 2018
$2.09M
Nov 7, 2018
Q2
2018
Jun 30, 2018
$2.58M
Aug 7, 2018
Q1
2018
Mar 31, 2018
$942.0K
May 10, 2018
Q3
2018
Sep 30, 2017
$1.15M
Nov 7, 2018
Q2
2018
Jun 30, 2017
$1.18M
Aug 7, 2018
Q1
2018
Mar 31, 2017
$1.46M
May 10, 2018
Q3
2017
Sep 30, 2016
$3.31M
Nov 2, 2017
Q2
2017
Jun 30, 2016
$3.72M
Aug 8, 2017
Q1
2017
Mar 31, 2016
$4.83M
May 9, 2017
Q3
2016
Sep 30, 2015
$4.94M
Nov 10, 2016
Q2
2016
Jun 30, 2015
$4.88M
Aug 11, 2016
Q1
2016
Mar 31, 2015
$2.58M
May 12, 2016
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$13.37M
Nov 10, 2025
Q2
2025
Jun 30, 2025
$5.20M
Aug 6, 2025
Q1
2025
Mar 31, 2025
$6.47M
May 6, 2025
Q3
2025
Sep 30, 2024
$24.63M
Nov 10, 2025
Q2
2025
Jun 30, 2024
$29.58M
Aug 6, 2025
Q1
2025
Mar 31, 2024
$19.52M
May 6, 2025
Q1
2024
Dec 31, 2023
$150.50M
May 13, 2024
Q3
2024
Sep 30, 2023
$4.61M
Nov 12, 2024
Q2
2024
Jun 30, 2023
$4.85M
Aug 6, 2024
Q1
2024
Mar 31, 2023
$150.48M
May 13, 2024
Q3
2023
Sep 30, 2022
$41.09M
Nov 6, 2023
Q2
2023
Jun 30, 2022
$712.0K
Aug 3, 2023
Q1
2023
Mar 31, 2022
$658.0K
May 9, 2023
Q3
2022
Sep 30, 2021
$1.48M
Nov 8, 2022
Q2
2022
Jun 30, 2021
$1.36M
Aug 4, 2022
Q1
2022
Mar 31, 2021
$6.50M
May 4, 2022
Q3
2021
Sep 30, 2020
$117.84M
Nov 2, 2021
Q2
2021
Jun 30, 2020
$28.68M
Aug 9, 2021
Q1
2021
Mar 31, 2020
$18.07M
May 10, 2021
Q3
2020
Sep 30, 2019
$20.43M
Nov 9, 2020
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($27.89M)
Nov 10, 2025
Q3
2025
Jun 30, 2025
($33.38M)
Nov 10, 2025
Q2
2025
Jun 30, 2025
($33.38M)
Aug 6, 2025
Q2
2025
Mar 31, 2025
($31.02M)
Aug 6, 2025
Q1
2025
Mar 31, 2025
($31.02M)
May 6, 2025
Q3
2025
Mar 31, 2025
($31.02M)
Nov 10, 2025
Q3
2025
Sep 30, 2024
($9.04M)
Nov 10, 2025
Q3
2025
Jun 30, 2024
($10.14M)
Nov 10, 2025
Q2
2025
Jun 30, 2024
($10.14M)
Aug 6, 2025
Q1
2025
Mar 31, 2024
($11.33M)
May 6, 2025
Q2
2025
Mar 31, 2024
($11.33M)
Aug 6, 2025
Q3
2025
Mar 31, 2024
($11.33M)
Nov 10, 2025
Q3
2024
Sep 30, 2023
($25.90M)
Nov 12, 2024
Q2
2024
Jun 30, 2023
($22.21M)
Aug 6, 2024
Q3
2024
Jun 30, 2023
($22.21M)
Nov 12, 2024
Q1
2024
Mar 31, 2023
$124.04M
May 13, 2024
Q3
2024
Mar 31, 2023
$124.04M
Nov 12, 2024
Q2
2024
Mar 31, 2023
$124.04M
Aug 6, 2024
Q3
2023
Sep 30, 2022
$17.62M
Nov 6, 2023
Q2
2023
Jun 30, 2022
($19.09M)
Aug 3, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($30.59M)
Nov 10, 2025
Q2
2025
Jun 30, 2025
($36.63M)
Aug 6, 2025
Q1
2025
Mar 31, 2025
($34.69M)
May 6, 2025
Q3
2025
Sep 30, 2024
($13.78M)
Nov 10, 2025
Q2
2025
Jun 30, 2024
($15.03M)
Aug 6, 2025
Q1
2025
Mar 31, 2024
($16.18M)
May 6, 2025
Q3
2024
Sep 30, 2023
($29.51M)
Nov 12, 2024
Q2
2024
Jun 30, 2023
($25.43M)
Aug 6, 2024
Q1
2024
Mar 31, 2023
$122.88M
May 13, 2024
Q3
2023
Sep 30, 2022
$14.44M
Nov 6, 2023
Q2
2023
Jun 30, 2022
($19.37M)
Aug 3, 2023
Q1
2023
Mar 31, 2022
($21.35M)
May 9, 2023
Q3
2022
Sep 30, 2021
($25.15M)
Nov 8, 2022
Q2
2022
Jun 30, 2021
($28.59M)
Aug 4, 2022
Q1
2022
Mar 31, 2021
($25.59M)
May 4, 2022
Q3
2021
Sep 30, 2020
$84.53M
Nov 2, 2021
Q2
2021
Jun 30, 2020
($8.98M)
Aug 9, 2021
Q1
2021
Mar 31, 2020
($24.43M)
May 10, 2021
Q3
2020
Sep 30, 2019
($17.81M)
Nov 9, 2020
Q2
2020
Jun 30, 2019
$9.19M
Aug 10, 2020